The integrated cancer services offered by Sarah Cannon will soon be supported by the personalized medicine technology platform of Syapse, to improve individualized patient care, the companies have announced.
Sarah Cannon the global cancer enterprise of Hospital Corporation of America (HCA) which offers cutting-edge clinical research alongside integrated cancer services and Syapse the leading provider of precision medicine software announced plans today to launch a precision oncology clinical service collaboration. The software-based service is designed to support Sarah Cannon’s efforts to make tumor genome profiling a key component of the care continuum for the more than 100000 newly diagnosed cancer patients seen annually across its network of cancer centers throughout the United States and United Kingdom.
Leaders from both organizations served on a panel to discuss genomic profiling in routine clinical care at the Personalized Medicine World Conference in Mountain View Calif. on January 27. The precision oncology platform to be launched in the second half of 2015 will assist in treatment planning and clinical decision-making by enabling Sarah Cannon care providers access to genomic testing best practice guidelines and decision support. It will also allow Sarah Cannon’s personalized medicine team to streamline genomic data analysis to improve patient outcomes and expand clinical trial options for patients.
Read the complete press release: http://bit.ly/1A79uOj